Sonnet BioTherapeutics Holdings, Inc. (SONN) Comparison with companies in other sectors?

Sonnet BioTherapeutics Holdings, Inc. has a share price of 6.26M. You can analyze Sonnet BioTherapeutics Holdings, Inc. (SONN) competitors across different market sectors through stock heatmaps.

What are SONN's NET and operating margins?

Sonnet BioTherapeutics Holdings, Inc. (SONN) operating margin is around -13.78, and net profit margin is approximately -13.29 as of the latest reports.

In what way does SONN's earnings per share (EPS) trend reflect its financial momentum?

Sonnet BioTherapeutics Holdings, Inc. (SONN) EPS is -12.07 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Sonnet BioTherapeutics Holdings, Inc. is -0.23, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Sonnet BioTherapeutics Holdings, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Sonnet BioTherapeutics Holdings, Inc. like P/E which is -0.83, P/B which is 16.70, and PEG which is 0.06. Compare them with sector averages to evaluate if the stock is priced fairly.

Sonnet BioTherapeutics Holdings, Inc.

SONN•NASDAQ

Healthcare

Biotechnology

$2.81

$-0.51(-15.36%)

Sonnet BioTherapeutics Holdings, Inc. (SONN) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-12.07

P/E Ratio

-0.23

ROE

-7.78%

Net Margin

-13.29%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$17.60M

Shares OutstandingTotal number of shares issued

$6.26M

Book Value/ShareNet worth per share

$0.17

Revenue/ShareAnnual revenue per share

$0.25

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-12.07

Net MarginNet income as percentage of revenue

-1328.60%

Operating MarginOperating income as percentage of revenue

-1378.09%

ROEReturn on shareholders' equity

-777.96%

ROAReturn on total assets

-346.31%

ROCEReturn on capital employed

-2080.88%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.97

Cash/ShareCash and equivalents per share

$0.53

FCF YieldFree cash flow as percentage of market cap

-67.17%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SONNFinancial Ratios Analysis details for SONN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SONNSector Benchmarking details for SONN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Sonnet BioTherapeutics Holdings, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Sonnet BioTherapeutics Holdings, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Sonnet BioTherapeutics Holdings, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Sonnet BioTherapeutics Holdings, Inc.

For Sonnet BioTherapeutics Holdings, Inc., essential financial indicators include EPS -12.07, PE -0.23, and ROE -7.78. These key ratios reveal insights into Sonnet BioTherapeutics Holdings, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Sonnet BioTherapeutics Holdings, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Sonnet BioTherapeutics Holdings, Inc.

Metrics like Net Margin -1328.60% and ROA -346.31% shed light on how well Sonnet BioTherapeutics Holdings, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Sonnet BioTherapeutics Holdings, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Sonnet BioTherapeutics Holdings, Inc.

Using ratios such as P/B Ratio 16.70 and PEG Ratio 0.06, investors can assess whether Sonnet BioTherapeutics Holdings, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Sonnet BioTherapeutics Holdings, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Sonnet BioTherapeutics Holdings, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.14 and Cash Flow $-2.97, provide a snapshot of Sonnet BioTherapeutics Holdings, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Sonnet BioTherapeutics Holdings, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Sonnet BioTherapeutics Holdings, Inc.

Investing in Sonnet BioTherapeutics Holdings, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Sonnet BioTherapeutics Holdings, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;